Cystic Fibrosis Frequently Asked Questions: Question 4: What is the appropriate duration of therapy for respiratory exacerbations in Cystic Fibrosis patients infected with Pseudomonas aeruginosa?
References (19)
Changes in strategies for optimal antibacterial therapy in cystic fibrosis
Int J Antimicrob Agents
(2001)Treatment of lung infection in patients with cystic fibrosis: current and future strategies
J Cyst Fibros
(2012)Optimising cystic fibrosis outcomes: screening and treating in 2013
Paediatr Respir Rev
(2012)Treatment of pulmonary exacerbations in cystic fibrosis
Eur Respir Rev
(2013)- et al.
Pathophysiology and management of pulmonary infections in cystic fibrosis
Am J Respir Crit Care Med
(2003) Antibiotic therapy against Pseudomonas aeruginosa in cystic fibrosis: a European consensus
Eur Respir J
(2000)Alginate overproduction affects Pseudomonas aeruginosa biofilm structure and function
J Bacteriol
(2001)- et al.
Management of refractory Pseudomonas aeruginosa infection in cystic fibrosis
Infect Drug Resist
(2011) Antibiotic treatment for cystic fibrosis, in Report of the UK Cystic Fibrosis Trust Antibiotic Working Group
(2009)
There are more references available in the full text version of this article.
Cited by (0)
Copyright © 2015 Published by Elsevier Ltd.